Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) is approved by the U.S. Food and Drug Administration to treat HER2-positive metastatic breast cancer that has previously been treated with Herceptin (chemical name: trastuzumab) and a taxane chemotherapy.

In this section you can learn more about:

Was this resource helpful?

Yes No
Back to Top